ANRO — Alto Neuroscience, Inc.
Is ANRO overbought or oversold? Here is the current MarketMoodz read.
Alto Neuroscience, Inc. (ANRO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $24.91. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$24.91
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Alto Neuroscience, Inc. is a clinical-stage neuroscience company whose valuation is driven largely by pipeline progress and occasional sector flows. With little evidence of commercial revenue in the supplied materials, near-term value depends on trial readouts, partnering activity, or financing outcomes. Market conditions described were calm with selective support for growth names, which may provide short-term lift but does not materially reduce the intrinsic binary risk tied to clinical results. Investors should monitor upcoming trial milestones, cash runway disclosures, and any partnership or M&A signals closely.
Key factors
- Clinical-stage neuroscience focus with pipeline and data-driven patient-matching approach that creates potential binary catalysts tied to trial readouts or partnerships
- No material commercial revenue disclosed in provided data; company profile implies reliance on capital markets or partners to fund development
- Broad market tone is measured risk-on with selective growth support, which can provide episodic buying interest for development-stage biotech names
- Potential strategic interest from larger pharma consolidating specialty franchises could create M&A optionality for assets or platform
- Limited public sentiment and EDGAR filing analysis available in the provided inputs increases uncertainty around near-term corporate developments
Risks
- Binary clinical-stage execution risk — negative trial data or missed endpoints could produce large and rapid share-price declines
- Cash burn and financing risk — lack of commercial cash flow raises probability of equity dilution or the need for dilutive financings
- Regulatory and reimbursement uncertainty for novel neuropsychiatric therapeutics can lengthen time to market and constrain near-term value capture
- Competitive pressure from large-cap pharma, specialty biotechs and alternative treatment modalities could limit long-term market share
- Low visibility into recent filings, social sentiment and near-term catalysts increases short-term volatility and execution uncertainty
See today's live rating, score and targets
Members see the live hourly rating for ANRO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.